First long-acting therapy with three-monthly dosing to target root cause of cardiac disease
News
FDA approves Keytruda and Keytruda Qlex with Padcev for bladder cancer
First PD-1 inhibitor plus ADC regimens for cisplatin-ineligible patients
Academy and Wellcome strengthen partnership with £27m agreement to boost UK health research
Five-year deal aims to support UK biomedical talent and drive collaboration across sectors
Bayer’s asundexian shows promise in landmark phase 3 stroke study
Positive topline results highlight potential new option for secondary stroke prevention
Gobivaz approved across Europe as first Simponi biosimilar
Alvotech and Advanz Pharma secure EC authorisation for treatment of immune-mediated diseases
Poolbeg granted European patent for POLB 001
New patent strengthens IP position for treatment of influenza side effects
TARA-002 shows strong early results in trial for paediatric lymphatic malformations
Protara’s phase 2 STARBORN-1 study reports high response rates and no serious adverse events
Libtayo approved in EU as first adjuvant immunotherapy for high-risk CSCC
New authorisation marks major milestone in earlier treatment of skin cancer
Cellbyte raises $2.75m to slash drug launch timelines with AI
Munich-based start-up backed by Frontline Ventures and Y Combinator eyes global expansion
GSK and Imperial launch £45m AI-powered AMR research drive
Six new Grand Challenges aim to tackle drug resistance and accelerate antibiotic discovery
Scottish Brain Sciences opens new Alzheimer’s research centre in Aberdeen
New ONE BioHub facility expands clinical trial access and strengthens Scotland’s brain health innovation
High dose nusinersen regimen receives positive CHMP opinion
New treatment option for spinal muscular atrophy moves closer to EU approval
Eisai shares long-term data on lecanemab at neurology congress
48-month analysis shows delayed progression and reduced risk in early Alzheimer’s patients
Mursla Bio partners with global pharma to advance precision medicine in liver disease
AI platform to support biomarker-guided therapy development in MASH
Evotec earns milestone payment as FDA clears IND for CELMoD candidate
US$5m payment from Bristol Myers Squibb marks progress in protein degradation partnership
